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ABSTRACT

Objective: To determine whether a Parkinson disease (PD)-specific biochemical signature might be
found in the total body metabolic milieu or in the CSF compartment, especially since this disorder
has systemic manifestations beyond the progressive loss of dopaminergic nigrostriatal neurons.

Methods: Our goal was to discover biomarkers of PD progression. Using ultra-high-performance
liquid chromatography linked to gas chromatography and tandem mass spectrometry, we measured concentrations of small-molecule (#1.5 kDa) constituents of plasma and CSF from 49
unmedicated, mildly affected patients with PD (mean age 61.4 years; mean duration of PD
11.4 months). Specimens were collected twice (baseline and final) at intervals up to 24 months.
During this time, mean Unified Parkinson’s Disease Rating Scale (UPDRS) parts 2 1 3 scores
increased 47% (from 28.8 to 42.2). Measured compounds underwent unbiased univariate and
multivariate analyses, including fitting data into multiple linear regression with variable selection
using least absolute shrinkage and selection operator (LASSO).
Results: Of 575 identified plasma and 383 CSF biochemicals, LASSO led to selection of 15 baseline plasma constituents with high positive correlation (0.87, p 5 2.2e216) to baseline-to-final
change in UPDRS parts 2 1 3 scores. Three of the compounds had xanthine structures, and 4
were either medium- or long-chain fatty acids. For the 15 LASSO-selected biomarkers, pathway
enrichment software found no overrepresentation among metabolic pathways. CSF concentrations of the dopamine metabolite homovanillate showed little change between baseline and final
collections and minimal correlation with worsening UPDRS parts 2 1 3 scores (0.29, p 5 0.041).

Conclusions: Metabolomic profiling of plasma yielded strong prediction of PD progression and offered
biomarkers that may provide new insights into PD pathogenesis. Neurology® 2017;88:862–869
GLOSSARY
CI 5 composite index; DATATOP 5 Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism; LASSO 5 least absolute shrinkage and selection operator; MS 5 mass spectrometry; PD 5 Parkinson disease; UPDRS 5 Unified Parkinson’s
Disease Rating Scale.

There has been a continuing challenge for improved methods to diagnose Parkinson disease
(PD) and to measure its progression. Despite extensive efforts to discover biochemical clues,
biomarkers with high specificity and sensitivity have been elusive1 (even in CSF, a compartment
contiguous with sites of neurodegeneration in the brain). This impasse applies also to measurements of substances integral to PD pathophysiology such as a-synuclein and dopamine metabolites, neither of which reliably differentiates individual cases of PD from controls.2
A fundamental challenge for biomarker discovery is to understand how broadly to seek the
imprint of PD. An earlier era regarded the pathology of PD as limited to dopaminergic neurons
in the substantia nigra, so focusing on diminished dopamine neurotransmission seemed reasonable for defining and monitoring the disease. However, manifestations of the core proteinopathy
of PD (a-synuclein aggregates) are demonstrable throughout the body.3 Even the bacterial population in the colon is altered in PD.4 The subcellular influence of PD throughout the body also
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resides in mitochondria5 and the proteasomelysosomal system.6 Hence, taking the search for
PD biomarkers into the total biochemical environment of the body seems warranted. This
approach, metabolomics, has become one of
the most productive technologies in recent biomarker research.7 With the latest methodologies, metabolomic analysis is capable of
measuring hundreds of low-molecular-weight
(,1.5 kDa) compounds in biospecimens,
characterizing a wide spectrum of the human
metabolic milieu.8–10 The unbiased analytic
methods for discerning biomarkers do not
depend on functional relationships between
biochemicals such as established metabolic
pathways. However, subsequent analysis can
investigate whether biomarker findings conform to known pathways11 and can search for
shared physicochemical properties (such as
evidence of oxidative stress).
Our goal was to learn whether metabolomic
profiling of CSF and plasma could help to predict the progression of PD. Specifically, we questioned how informative an initial biochemical
profile or its change in a later specimen collection might be for predicting disease progression.
We also investigated whether the CSF concentration of homovanillate, the major metabolite
of dopamine,12 predicted worsening PD.
METHODS Participants. Participants with relatively mild
parkinsonism provided CSF and plasma samples in the
DATATOP (Deprenyl and Tocopherol Antioxidative Therapy
of Parkinsonism) clinical trial.13 During this trial, participants
underwent blinded assessments with the Unified Parkinson’s
Disease Rating Scale (UPDRS).14 In the current study, we measured change in parkinsonism over time with UPDRS questions
pertaining to activities of daily living (part 2) and motor examination (part 3). A composite index (CI) of parkinsonism was the
sum of scores from both parts (UPDRS2 1 3).
In the DATATOP study, participants could not receive
symptomatic treatment for PD.13 Our study used specimens from
49 randomly selected placebo-treated participants for whom the
enrolling investigator confirmed (retrospectively with $90% certainty) that the PD diagnostic impression was correct. Specimens
came from 33 men (67% of total group; mean age at enrollment
61.4 years, range 38–74 years) and 16 women (mean age 65.9
years, range 46–78 years). The total group mean 6 SD age was
62.9 6 7.7 years. Mean duration of parkinsonian symptoms
before initial (baseline) assessment was 11.4 6 4.7 months (range
3.0–22.3 months). At baseline, mean UPDRS part 2 score was
8.5 (range 3–15) and mean part 3 score was 20.3 (range 3–38.5).
At the second (final) specimen collection, mean part 2 score was
12.9 (range 4–22) and part 3 score was 29.3 (range 6–49).

Standard protocol approvals, registrations, and patient
consents. At each study site, the DATATOP trial received

approval from institutional ethics standards committees on
human experimentation. Written informed consent was obtained
from all patients participating in the study.

Collection procedures. Lumbar puncture CSF and venous
plasma specimens were collected by standardized methods at
study enrollment (baseline) and at trial completion (final)13,15
when UPDRS assessments also were conducted. While DATATOP
study participation was up to 2 years, intervals between baseline
and final testing were shorter if participants met endpoint
criteria (defined as worsening of parkinsonism requiring start of
dopaminergic therapy13).
CSF and blood specimens were collected after overnight bed rest
(between 6 and 10 AM before breakfast). Lumbar CSF was removed
in sequential measured aliquots. We used the specimen pooled from
12 to 14 mL and without blood contamination. Specimens were
immediately chilled and stored at 2708C until assayed.15
Assay methods. Detailed methods for the metabolomic profiling
of the CSF and plasma specimens have been reported.8–10,16 In summary, samples were extracted and split into aliquots for analysis on 3
separate mass spectrometers (Thermo Scientific, Waltham, MA):
ultra-high-performance liquid chromatography–mass spectrometry
(MS) OrbiElite System for detecting positive and negative ions and
a Trace Ultra Gas Chromatograph-DSQ-MS system. For the 2 liquid
chromatography methods, chromatographic separation followed by
full-scan mass spectra was carried out to record retention time,
molecular weight (m/z), and tandem MS of all detectable ions. For
gas chromatography, the samples were derivatized with bistrimethylsilyl-triflouroacetamide. Retention time and m/z were measured.
Bioinformatics. Data extracted from the raw MS data files were
loaded into a relational database and evaluated without binary largeobject manipulation.10 Peaks were identified with proprietary peak
integration software,17 and components were stored in a specifically
designed complex data structure. Compounds were identified by
comparison of the ion features of each sample to reference library
entries of chemical standard entries (retention time, m/z, preferred
adducts, and in-source fragments) and their associated tandem MS
spectra.17 Several quality control and curation procedures were
conducted for a high-quality data set with accurate and consistent
identification of chemical entities and for removing system artifacts,
misassignments, and background noise.8,10
Statistical analysis. The 49 samples per group (baseline and
final) exceeded the group size of 20 to 25 generally required for adequate statistical modeling of metabolomic data.18 Any compound
for which data had missing values (due to thresholding of MS data,
for example) was imputed by use of minimum detection level. Data
was log2 transformed. To detect biochemicals of interest, data
underwent a strategy of feature selection through univariate analysis
followed by multivariable modeling. False discovery rate–adjusted p
values were calculated for the univariate analysis.19
To investigate for biomarkers of PD progression, we took several approaches. With baseline assay data, a univariate analysis
determined whether any of the biochemicals was associated with
PD progression, defined as change in parkinsonian severity (difference between UPDRS parts 2 1 3 scores at baseline and final
assessments [DUPDRS2 1 3]). This analysis involved calculation
of the Pearson correlation. Another investigation was for a possible
association between DUPDRS2 1 3 and the CSF concentration of
the dopamine metabolite homovanillate. A third analysis was to
develop a multimarker predictive model with the goal of determining a panel of compounds that might predict DUPDRS2 1 3. The
method chosen was multiple linear regression with variable selection using least absolute shrinkage and selection operator
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(LASSO).20 Ten-fold cross-validation was performed on LASSO to
yield an unbiased estimate of prediction error so that the best
number for the combination of markers could be selected.
Another data analysis approach was to determine which plasma
and CSF biochemicals had changed in concentration from baseline
to the final collection. Similar to the analytic methods described
above, a univariate analysis determined whether individual compounds showing baseline-to-final change was associated with
DUPDRS2 1 3. Finally, we generated a multimarker model with
LASSO to explore for a panel of CSF and plasma compounds for
which a change in concentration could predict PD progression.
Metabolomic data also can be studied from known metabolic
relationships between assayed biochemicals with KEGG pathway
maps (www.genome.jp) and other sources of biochemical information. For this investigation, results obtained from pathway
enrichment analysis were combined with a topology analysis
(Ingenuity Pathway Analysis, Ingenuity Systems, Mountain
View, CA) to discern where there was overrepresentation by
any of the detected biomarkers.

CSF biochemicals. Each compound was identified by
reference to entries in the Metabolon chemical library.17
Analysis of baseline metabolomic data. Pearson correla-

tion coefficients and corresponding p and q values were
calculated for concentrations of biochemicals measured
in CSF and plasma samples. Some of the data showed
up to a moderate correlation with DUPDRS2 1 3
(approximately 60.4, with corresponding values of
p ,0.01). However, none of these compounds maintained statistical significance in their correlations after
p value adjustment. Correlations found in plasma samples were, in general, consistent with the correlations
found in the CSF samples, although there was some
variability. Because none of the measured plasma or
CSF biochemicals achieved statistical significance after
adjustment, we created lists of the top 10 compounds
that, of all the measured compounds, showed the
greatest correlations to DUPDRS2 1 3 (table 1). For

RESULTS Assay findings. The assays detected and
measured 575 structurally distinct plasma and 283

Table 1

Univariate analysis of baseline assay data to determine those biochemicals associated with change in
parkinsonian severity (defined as the difference between Unified Parkinson’s Disease Rating Scale
parts 2 1 3 scores determined at baseline and final assessments)
Plasma

A

Correlation

CSF
p

q

Correlation

p

10-Nonadecenoate (19:1n9)

0.4149

0.0030

0.214184

ND

ND

3-Hydroxydecanoate

0.4519

0.0011

0.214184

ND

ND

5-Dodecenoate (12:1n7)

0.4190

0.0027

0.214184

ND

ND

Docosadienoate (22:2n6)

0.4150

0.0030

0.214184

ND

ND

Docosatrienoate (22:3n3)

0.4305

0.0020

0.214184

ND

ND

Eicosenoate (20:1n9 or 11)

0.4442

0.0014

0.214184

ND

ND

Mannitol

0.3854

0.0062

0.32128

0.3152

0.0274

Myristoleate (14:1n5)

0.4169

0.0029

0.214184

ND

ND

Palmitoleate (16:1n7)

0.3996

0.0044

0.279114

ND

ND

20.4537

0.0011

0.214184

20.1981

0.1723

Serine

CSF

Plasma

B

Correlation

p

q

Correlation

p

2-Ethylhexanoic acid

20.3784

0.0073

0.775332

ND

ND

Benzoate

20.4226

0.0025

0.683794

20.0798

0.5855

Dodecanedioate

0.2738

0.0569

0.984611

ND

ND

Homovanillate

0.2924

0.0414

0.984611

ND

ND

Indoleacetate

0.2923

0.0416

0.984611

0.0785

0.5917

Mannitol

0.3152

0.0274

0.984611

0.3854

0.0062

20.2703

0.0603

0.984611

20.1720

0.2372

N-6-trimethyllysine

0.3697

0.0089

0.775332

0.0612

0.6760

Oxalate

0.2815

0.0501

0.984611

0.1638

0.2607

Tartrate

0.3591

0.0113

0.775332

0.0454

0.7566

Methyl-b-glucopyranoside

Abbreviation: ND 5 not detected.
Listed are the top 10 compounds in plasma and CSF with concentrations that showed the highest Pearson correlations.
A. The top 10 compounds found in baseline plasma samples and the corresponding results in baseline CSF samples.
B. The top 10 compounds found in baseline CSF samples and the corresponding results in baseline plasma samples.
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example, analysis of the baseline plasma specimens
listed in table 1 found that serine concentration was
inversely correlated with DUPDRS2 1 3 (20.45, p 5
0.0011). In CSF, serine was not as strongly inversely
correlated with DUPDRS2 1 3 (20.20, p 5 0.17).
For the top 10 compounds in CSF samples with correlations to DUPDRS2 1 3 (table 1), the strongest
relationship was an inverse correlation with benzoate
(20.42, p 5 0.0025). Measurement of benzoate in
plasma samples did not correlate with DUPDRS2 1 3.
In a further analysis using LASSO (table 2), we
identified 15 compounds from profiling baseline
plasma specimens that, together as a group, best predicted DUPDRS2 1 3. From these data, we created a
CI based on a linear combination of these compounds
using the coefficients listed in table 2 (figure, A). This
analysis yielded a high correlation coefficient (0.87, p 5
2.2e216) between the CI and DUPDRS2 1 3. A similar analysis with LASSO was carried out for compounds in the baseline CSF profiles, which identified
2 biochemicals, benzoate and N-6-trimethyllysine, that
best predicted DUPDRS2 1 3 (table 2). Using a similar
calculation for CI, we then fitted the coefficients for the
baseline CSF compounds in the linear regression

Table 2

From baseline plasma and CSF assay results, the best combination of
compounds with concentrations selected by least absolute shrinkage
and selection operator20 and fitted in a linear regression

A

Coefficient

SE

p

Intercept

12.66

1.21

0.0000

1-Arachidoylglycerophosphocholine (20:0)

20.51

0.72

0.4785

1-Methylxanthine

0.41

0.61

0.5061

3-Hydroxydecanoate

1.90

2.15

0.3822

5-Dodecenoate (12:1n7)
5a-Androstan-3b-17a-diol-disulfate
Docosadienoate (22:2n6)
Docosatrienoate (22:3n3)

2.00

2.04

0.3334

20.87

0.60

0.1551

1.29

3.04

0.6727

0.86

2.16

0.6913

Ethyl glucuronide

20.53

0.80

0.5124

Iminodiacetate

21.46

2.05

0.4832

Inosine

23.45

1.00

0.0015

1.95

0.96

0.0508

Picolinate

22.50

1.60

0.1279

Serine

24.30

2.44

0.0870

Taurine

21.77

1.58

0.2721

0.47

0.47

0.3202

Mannitol

Theobromine
B
Intercept
Benzoate
N-6-trimethyllysine

Coefficient
13.15543
215.6165
9.374373

SE

p

0.990786

2.40e217

4.218781

0.000571

2.852311

0.001946

A. Multiple regression findings using the 15 selected markers from baseline plasma
samples.
B. Multiple regression findings using the 2 selected markers from the baseline CSF samples.

model. Figure, B shows that this CI was moderately
correlated (0.58, p 5 1.33e25) with DUPDRS2 1 3.
Analysis of metabolomic data that showed change from
baseline to final collections. Correlation coefficients and

corresponding p values were investigated for CSF and
plasma samples; they showed moderate (.60.4) correlations between concentration changes and DUPDRS2
1 3. We created a list of the top 10 compounds with
changes from baseline to final that showed the greatest
correlation to DUPDRS2 1 3 (table 3). For example,
the change in plasma phenylcarnitine concentrations
was moderately correlated with DUPDRS2 1 3
(0.48, p z 0.0004). The concentration of phenylcarnitine in CSF was below the detection limit. In CSF, the
strongest correlation with DUPDRS2 1 3 was change
in benzoate concentration (0.48, p z 0.0005).
For plasma specimens, change in concentration
from baseline to final for a group of 3 compounds
(1,3-dimethylurate, aspartylphenylalanine, and phenylcarnitine) best predicted DUPDRS2 1 3 (table
4). From these data, we created a CI based on the
coefficient for changes in each marker. This CI correlated with DUPDRS2 1 3 (0.67, p 5 1.54e216).
For similar analysis of CSF, benzoate was the only
compound selected by LASSO; hence, its result was
the same as that shown by univariate analysis (0.48,
p 5 0.00045). Between baseline and final, the mean
CSF concentration of the dopamine metabolite
homovanillate showed little change and only weakly
correlated with DUPDRS2 1 3 (0.29, p 5 0.041).
DISCUSSION This study combined analysis of CSF
and plasma samples in an effort to discover PD state
(disease progression) markers. These observations
underscore the value of untargeted metabolomic
screening of clues for a disorder that is known to have
diverse systemic manifestations. Although our analysis
discerned a biochemical profile linked to PD progression, these findings do not clarify whether the observed
markers represent primary biochemical manifestations
of the disease process or “downstream” changes (or
even epiphenomena of PD). Regardless of their origins,
discovery of compounds with CIs that are highly predictive of DUPDRS2 1 3 may provide a useful supplement to clinical monitoring of PD progression (and
might constitute a preclinical indicator). The information from this metabolomic investigation might also
have a place in a meta-analysis for which other
biomarker candidates (such as a-synuclein, Ab1-42,
or fraktaline measurements21) might be incorporated
for enhancing correlations to PD progression.
In contrast to several earlier metabolomic methodologies used with PD biospecimens,22–26 our analytic
platform possesses greatly improved capabilities for
biochemical detection and identification. We also
Neurology 88
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Figure

Correlations between composite indexes and baseline-to-final changes in UPDRS parts 2 1 3 scores

(A) Composite index for baseline plasma specimens (correlation coefficient 5 0.87, p 5 2.2e216). (B) Composite index for
baseline CSF specimens (correlation coefficient 5 0.58, p 5 1.33e25). UPDRS 5 Unified Parkinson’s Disease Rating Scale.

avoided the potentially confounding effects of PD
drugs (such as levodopa27) by using samples only from
unmedicated participants. Earlier biomarker investigations into PD progression have focused on measures of striatal dopaminergic neurotransmission.
While homovanillate is the predominant metabolite
and the end product of dopamine catabolism in humans,12 previous studies of CSF homovanillate concentration have yielded inconsistent results as to the
utility of this compound for cross-sectional analysis of
PD severity or for distinguishing patients with PD
from healthy controls.28 The current study confirms
that CSF homovanillate is not a useful biomarker of
PD progression.
CSF specimen findings. Of the 373 biochemicals iden-

tified in CSF, benzoate was the only one with
a change in concentration from baseline to final that
provided even moderate prediction of DUPDRS2 1 3
(0.48, p 5 0.00045). This compound, which is
derived from the catabolism of phenylalanine (a precursor of catecholamines), is also a common food
additive. Because CSF benzoate concentrations
exceed those in plasma, it likely originates from
endogenous metabolism rather than diet. In plasma
specimens, another metabolite derived from phenylalanine, the dipeptide aspartylphenylalanine, also
changed substantially between the baseline and
final collections. The LASSO-selected combination
of aspartylphenylalanine, 1,3-dimethylurate, and
phenylcarnitine (table 4) provided a correlation
coefficient of 0.67 (p 5 1.54e216) with DUPDRS2 1 3.
Surprisingly, neither of these biochemicals was
866

Neurology 88

among the 15 plasma constituents selected from
baseline data (table 2) that, as a group, provided
strong prediction of DUPDRS2 1 3.
Plasma specimen findings. As illustrated in the figure,

the best prediction of PD progression arose from a panel
of compounds measured in plasma specimens,
with a remarkably high correlation coefficient of 0.87
(p 5 2.2e216). Furthermore, the best predictor for
DUPDRS2 1 3 was in baseline specimen data rather
than the change in concentrations from baseline to final.
Purine metabolism findings. For the 15 plasma biochemicals selected by LASSO for fitting in linear
regression analysis (table 2), a search with pathway
enrichment software found no overrepresentation
among metabolic pathways. However, we found some
classes of biochemicals (including several purine compounds) that were predictive of worsening parkinsonism.
A previous metabolomic study also found several
purines with concentrations that differentiated PD
plasma samples from controls.24 Our prior metabolomic analysis of postmortem CSF (which compared PD
to control samples) also reported that the purine inosine
was among 19 compounds found to offer the best
differentiation.16 The current data for baseline plasma
inosine (table 2) reveal that this compound has a moderate inverse correlation with DUPDRS2 1 3 (23.53,
p 5 0.013). Four metabolites of the purine compound
caffeine were among the biochemicals found to be biomarkers of PD progression: theobromine, theophylline,
paraxanthine, and 1-methylxanthine. Between the
baseline and final specimen collections, the mean
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Table 3

Univariate analysis of compounds with concentrations that changed from baseline to final collections,
correlated with change in parkinsonian severity (defined as the difference between Unified
Parkinson’s Disease Rating Scale parts 2 1 3 scores determined at baseline and final assessments)
Plasma

A
Phenylcarnitine

Correlation
0.482961

CSF
p

q

p

Correlation

0.00044

0.249078

ND

ND

Aspartylphenylalanine

20.42394

0.002401

0.675916

ND

ND

Theophylline

20.39724

0.00471

0.675916

20.25068

0.082327

1,3-Dimethylurate

20.38828

0.005836

0.675916

ND

ND

Pyruvate

20.37469

0.007989

0.675916

20.01141

0.937975

Cyclo(leu-pro)

20.37169

0.008549

0.675916

20.25464

0.077451

3-Methyl-2-oxobutyrate

20.37084

0.008713

0.675916

20.09716

0.506612

Fumarate

0.009943

0.675916

ND

ND

a-Ketobutyrate

20.35569

0.364885

0.012136

0.675916

20.26236

0.068586

Paraxanthine

20.34864

0.014087

0.675916

20.2247

0.120614

CSF
B
2-Ethylhexanoic acid
2-Methylbutyroylcarnitine
Benzoate

Correlation
0.428031
20.38392
0.481587

Plasma
p

q

p

Correlation

0.002155

0.253906

ND

ND

0.006463

0.253906

ND

ND

0.000459

0.126341

0.171142

0.239689

Carnitine

20.35228

0.013047

0.354153

20.24322

0.092184

Cytidine

20.36488

0.009944

0.303846

0.074131

0.612705

Isobutyrylcarnitine

20.40623

0.003776

0.253906

ND

ND

Isovalerylcarnitine

20.38973

0.005639

0.253906

ND

ND

Propionylcarnitine

20.39852

0.004566

0.253906

ND

ND

Quinate

0.370407

0.008797

0.30241

0.070293

0.631266

Xylose

0.391176

0.005449

0.253906

ND

ND

Abbreviation: ND 5 not detected.
Listed are the top 10 compounds in plasma and CSF with changes in concentration that showed the highest Pearson
correlations.
A. The top 10 compounds found in plasma samples and the corresponding results in CSF samples.
B. The top 10 compounds found in CSF samples and the corresponding results in plasma samples.

plasma concentration of one of them, theobromine,
decreased by z8%. While this change could be
attributed to diminished dietary intake of caffeine at
the time when final specimens were collected,
another explanation might be a progressive change for
overall purine metabolism (as reflected in the
metabolism of both endogenous and dietary xanthine
compounds). The latter hypothesis has support from
our findings with inosine, the mean plasma
concentration of which at the final collection was
decreased by almost one-third from baseline.
Evidence from other sources also implicates
altered purine metabolism in PD. One study found
that several purine-metabolism genes in the PD brain
were either upregulated or downregulated compared
to controls.29 Epidemiologic research has also highlighted relationships between PD and purine compounds. For example, habitual dietary intake of

caffeine imparts a strong inverse association in the
risk for developing PD.30 Other inverse correlates of
risk for either the acquisition or progression of PD are
reported with both plasma and CSF concentrations of
urate (2,6,8-trioxypurine).31 The depletion of striatal
dopamine in the PD brain might also influence
purine metabolism.32
Fatty acids and lipid metabolism findings. In the baseline

plasma specimens, we found another category of
biochemicals among the 15 compounds predictive of
PD progression (table 2): 4 medium- and long-chain
fatty acids (5-dodecanoate, 3-hydroxydecanoate,
docosadienoate, and docosatrienoate) and the lysolipid
1-arachidoylglycerophosphocholine. Although these
and related compounds have not been implicated
previously in the neurodegenerative process of PD,
experimental evidence from toxin-induced rodent
Neurology 88
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Table 4

From change in measured concentrations between baseline and final
biospecimen collections, the best combination of plasma and CSF
compounds that were selected by least absolute shrinkage and
selection operator20 and fitted in a linear regression

A

Coefficient

SE

p

Intercept

13.76717

0.918581

4.13e219

1,3-Dimethylurate

22.06383

0.681295

0.004052

Aspartylphenylalanine

23.7813

2.178217

0.089414

Phenylcarnitine

1.628097

0.000276

B

Estimate

6.423856

SE

p

Intercept

13.21602

1.044155

9.46e217

Benzoate

12.93255

3.432904

0.000459

A. Multiple regression using changes in the 3 selected markers from plasma samples.
B. Multiple regression using change in the one selected marker (benzoate) in CSF samples.

metabolomic findings needs to recognize that, beyond
profiling biochemicals involved in endogenous metabolism, the measured compounds also can originate from
diet, other ingested substances, and gut flora. Standardized biospecimen collection methods and participant
groups of adequate size18 are critical for reducing some
of the potential artifacts in metabolomic studies.
Our findings offer biomarkers for studying PD
progression and, with them, several new directions
for investigation of PD pathogenesis. We intend to
replicate these findings using other sample sets and
hope to determine whether the compounds found
to predict PD progression might also serve to differentiate those with PD from healthy controls or from
those with other neurodegenerative disorders.
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